Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients

Annals of Oncology : Official Journal of the European Society for Medical Oncology
U VitoloL Resegotti

Abstract

B-diffuse large-cell lymphomas (DLCL) have been associated with some molecular lesions, but the role of such lesions as prognostic markers is still controversial. This report concerns an investigation of the frequency and clinical correlation of bcl-6, bcl-2, c-myc rearrangements and 6(q) deletions in B-DLCL. The presence of these genetic lesions was analyzed in samples of lymph nodes or bone marrow collected at diagnosis in 71 patients with B-DLCL, all treated with an anthracycline-containing chemotherapy regimen. Rearrangement of bcl-6 was found in 11 patients (15%), rearranged bcl-2 in 12 (17%), 6(q) deletions in 10 patients (14%) and c-myc rearrangement in four (6%). Patients with rearranged bcl-6 tended to have a more aggressive disease than patients with germ-line bcl-6 (intermediate-high/high risk according to IPI criteria: 73% vs. 43%), but there were no differences in three-year survival rates (62% vs. 42%) between the two groups. The numbers of involved extranodal sites were similar in patients with rearranged and those with germ-line bcl-6. Patients with bcl-2 rearrangement appeared to have a less aggressive disease than those with germ-line bcl-2 (low/ low-intermediate risk 75% vs. 47%) and a slightly better three-y...Continue Reading

Citations

May 16, 2000·Cancer Investigation·B H Ye
Apr 13, 2000·American Journal of Clinical Pathology·C C ChangS L Perkins
Jun 24, 2009·Advances in Anatomic Pathology·Jonathan Said
Jul 28, 2010·American Journal of Clinical Pathology·David K DurnickEllen D McPhail
Sep 24, 2014·Archives of Pathology & Laboratory Medicine·Elizabeth C Chastain, Eric J Duncavage
Jun 23, 1999·Oncogene·C E NesbitE V Prochownik
Oct 22, 2002·Journal of Neuropathology and Experimental Neurology·Manuel Montesinos-RongenReiner Siebert
Aug 18, 2004·Current Opinion in Oncology·Randy D Gascoyne
Jun 11, 2017·Blood·Jonathan W Friedberg
Mar 16, 2019·Immunological Reviews·Andrea BissoBruno Amati
Aug 3, 2002·Leukemia & Lymphoma·C KawasakiM Kikuchi
Mar 16, 2000·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·K PetersH K Müller-Hermelink
Jun 30, 2005·Cancer·Megan L TroxellChristina S Kong
Jul 10, 2007·International Journal of Laboratory Hematology·A J BenchM A Scott
Dec 6, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·B E KingS H Swerdlow
May 17, 2005·Applied Immunohistochemistry & Molecular Morphology : AIMM·Yin XuSteven H Kroft
Jul 16, 2005·Hematology·Fabrice Jardin, Surinder S Sahota
Dec 7, 2002·Hematological Oncology·Huifeng Niu
Oct 3, 1999·Current Opinion in Oncology·A Sarris, R Ford
May 1, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shotaro NakamuraMing-Qing Du
Dec 24, 2005·Pathology·Lynda J Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.